These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26188396)

  • 21. Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure.
    Haaber J; Friberg C; McCreary M; Lin R; Cohen SN; Ingmer H
    mBio; 2015 Jan; 6(1):. PubMed ID: 25587013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of oritavancin against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA).
    Saravolatz LD; Pawlak J; Johnson LB
    Int J Antimicrob Agents; 2010 Jul; 36(1):69-72. PubMed ID: 20413274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MRSA--the tip of the iceberg.
    Appelbaum PC
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1376-83. PubMed ID: 16569855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Domenech A; Ribes S; Cabellos C; Taberner F; Tubau F; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F
    J Antimicrob Chemother; 2005 Oct; 56(4):709-16. PubMed ID: 16120625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections.
    Domenech A; Ribes S; Cabellos C; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F
    Microb Drug Resist; 2004; 10(4):346-53. PubMed ID: 15650381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model.
    Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
    Antimicrob Agents Chemother; 2012 Jan; 56(1):243-7. PubMed ID: 22064531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
    Andes D; Craig WA
    Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
    Kitzis MD; Goldstein FW
    Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Rose WE; Knier RM; Hutson PR
    J Antimicrob Chemother; 2010 Oct; 65(10):2149-54. PubMed ID: 20693174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
    Dandekar PK; Tessier PR; Williams P; Nightingale CH; Nicolau DP
    J Antimicrob Chemother; 2003 Sep; 52(3):405-11. PubMed ID: 12917254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.
    Moise PA; North D; Steenbergen JN; Sakoulas G
    Lancet Infect Dis; 2009 Oct; 9(10):617-24. PubMed ID: 19778764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore.
    Fong RK; Low J; Koh TH; Kurup A
    Eur J Clin Microbiol Infect Dis; 2009 Aug; 28(8):983-7. PubMed ID: 19387707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance.
    Rong SL; Leonard SN
    Ann Pharmacother; 2010 May; 44(5):844-50. PubMed ID: 20332341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glycopeptide resistant Staphylococcus.
    Witte W
    J Vet Med B Infect Dis Vet Public Health; 2004; 51(8-9):370-3. PubMed ID: 15525368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing Thiram and Disulfiram as Antibacterial Agents for Multidrug-Resistant Staphylococcus aureus Infections.
    Long TE
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.
    Kelley PG; Gao W; Ward PB; Howden BP
    J Antimicrob Chemother; 2011 May; 66(5):1057-60. PubMed ID: 21393156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.
    Cui L; Iwamoto A; Lian JQ; Neoh HM; Maruyama T; Horikawa Y; Hiramatsu K
    Antimicrob Agents Chemother; 2006 Feb; 50(2):428-38. PubMed ID: 16436693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.